Optimal Dose of Combination of Rocuronium and Cisatracurium

• Status: Completed
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

BACKGROUND: The combinations of rocuronium and cisatracurium have a synergic effect. The investigators studied whether the prediction is possible to have a sufficient effect of reducing the dose when combining the two neuromuscular blocking agents through monitoring neuromuscular relaxation during surgery.

METHODS: Each group were intubating dose group (Group I, n=27) combined Effective Dose (ED)95 rocuronium and ED95 cisatracurium, small amount reducing group (Group S, n=27) reduced 10% of each ED95 and large amount reducing group (Group L, n=27) reduced 20% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each study drug was administrated to the patient and timer was started with TOF-Watch® monitoring. Train-of-four (TOF) of the ulnar nerve was used as setting of 2 Hz per 12 sec. The investigators checked time to TOF ratio=0 (Onset), time to 1st TOF ratio>25% (Duration 25%) and TOF 25-75% (recovery index) under total i.v. anesthesia (TIVA). One way ANOVA was used for statistical analysis (α=0.05, β=0.2).

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yonsei University
• Treatments: Atracurium; Cisatracurium; Rocuronium

Criteria

Inclusion Criteria:

• the American Society of Anesthesiologists (ASA) physical status I-II

• BMI 20-30 kg/m2

• Patients scheduled for mastoidectomy and tympanoplasty.

Exclusion Criteria:

• a history of allergy to the study drugs,

• neuromuscular disease,

• pregnancy

• breast-feeding,

• preoperative medication of antipsychotics or neuroleptics known to interact with NMBAs

• serum creatinine level>1.2 mg/dL,

• liver transaminase>40 U/L.